Dr. Chen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 SW Sam Jackson Park Rd
# UHN73C
Portland, OR 97239Phone+1 503-494-5058
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology and Medical Oncology, 2005 - 2009
- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2001 - 2004
- Harvard Medical SchoolClass of 2001
Certifications & Licensure![](https://directory.doximity.com/assets/icons/icon-help-e9f0b148a1e6d1f037dde9f26f025c36bd7c99fd4fe31fd76792996fa2aa5e66.svg)
- HI State Medical License 2024 - 2026
- CA State Medical License 2002 - 2025
- OR State Medical License 2009 - 2025
- WA State Medical License 2022 - 2025
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Sociodemographic Factors Influencing Access to Chimeric Antigen T-Cell Receptor Therapy for Patients With Non-Hodgkin Lymphoma.Somya Khare, Staci Williamson, Brittany O'Barr, Levanto Schachter, Andy Chen
Clinical Lymphoma, Myeloma & Leukemia. 2025-02-01 - Lisocabtagene Maraleucel for Relapsed/Refractory Large B-Cell Lymphoma: A Cell Therapy Consortium Real-World Analysis.Peter A Riedell, Connor B Grady, Loretta J Nastoupil, Alejandro Luna De Abia, Nausheen Ahmed
Blood Advances. 2024-12-10 - 1 citationsOptimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.Nausheen Ahmed, William Wesson, Forat Lutfi, David L Porter, Veronika Bachanova
Blood Advances. 2024-10-22
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: